Riskpilot← Back to searchSign inGet full accessKnape Medical Oy
OYActiveY-tunnus 3185847-2Kaj Franckin Katu 1-A8General medical practice activities · NACE 8621Est. 20211 employees
Revenue 2025
EUR 47K
-83% vs 2024
EBITDA margin
6.0%
-98% vs 2024
Equity ratio
99.4%
Financial strength
Net profit 2025
EUR -220
-100% vs 2024
| Revenue | EUR 47K | -83% |
| EBITDA | EUR 3K | -98% |
| Net profit | EUR -220 | -100% |
| Total assets | EUR 320K | -8% |
| Equity | EUR 319K | -8% |
| Employees | 1 | — |
Legal name
Knape Medical Oy
Y-tunnus number
3185847-2
Legal form
Osakeyhtiö
NACE code
8621 · General medical practice activities
Founded
25. tammikuuta 2021
Share capital
EUR 0
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsenet ja toimitusjohtaja kukin yksin
Company purpose
Yhtiön toimialana on lääketieteellinen tutkimus, hoito- ja konsultaatiotoiminta sekä niihin liittyvien välineiden ja tarvikkeiden kauppa. Lisäksi yhtiö voi omistaa, hallita, vuokrata ja käydä kauppaa kiinteistöillä, osakkeilla, osuuksilla ja arvopapereilla
Address
Kaj Franckin Katu 1-A8
Phone
+3580505934063
Email
rony-knape@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 207 | 273 | 274 | 276 | 47 |
| Staff expenses | −34 | −145 | −130 | −132 | −12 |
| EBITDA | 161 | 115 | 116 | 118 | 3 |
| Depreciation & amort. | — | — | −5 | −8 | −6 |
| EBIT | 161 | 115 | 110 | 111 | −3 |
| Net financials | 4 | −16 | 12 | 1 | 3 |
| Profit before tax | 165 | 99 | 122 | 111 | −0 |
| Tax | 33 | 23 | 22 | 23 | −0 |
| Net profit | 132 | 76 | 99 | 89 | −0 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 168 | 201 | 289 | 347 | 320 |
| Equity | 132 | 198 | 280 | 346 | 319 |
| Long-term debt | — | — | 0 | 0 | 0 |
| Short-term debt | 36 | 4 | 9 | 0 | 2 |
| Total debt | 36 | 4 | 9 | 0 | 2 |
EBITDA margin
6.0%
This company
15.8%
Market median
-62% vs market
20212025
Equity ratio
99.4%
This company
38.2%
Market median
+160% vs market
20212025
Return on equity
-0.1%
This company
18.4%
Market median
-101% vs market
20212025
Net profit margin
-0.5%
This company
8.1%
Market median
-106% vs market
20212025
Asset turnover
0.15×
This company
1.12×
Market median
-87% vs market
20212025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
TJ Deputy auditor | Deputy auditor | 2023 |
RP Chief Executive Officer | Chief Executive Officer | 2021 |
JP Audit | Audit | 2023 |
RE Deputy Member | Deputy Member | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairperson | 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Knape Medical Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Timo Jaakko Ollila | Deputy auditor | 0 companies |
| Rony Petri Johannes Knape | Chief Executive Officer | 0 companies |
| Juha Pentti Pesola | Audit | 0 companies |
| Rina Emilia Knape | Deputy Member | 0 companies |
| Rebekka Susanna Knape | Chairperson | 0 companies |